Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie. AbbVie will acquire Capstan, including CPTX2309 a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 chimeric antigen receptor T-cell therapy candidate currently in Phase 1 for treating B cell-mediated autoimmune disease – as well as Capstan’s proprietary tLNP platform technology, which delivers RNA payloads, such as messenger RNA (mRNA), to engineer specific cell types in vivo. Under the terms of the agreement, AbbVie will pay up to $2.1 billion in cash at closing, subject to certain customary adjustments.
Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie